Decreased RNA expression of interleukin 17A in skin of leprosy

European Journal of Dermatology

Volumn 22, Issue 4, 2012, Pages 488-494

  Da Motta Passos, Isabella ^a   Malheiro, Adriana ^a,b   Gomes Naveca, Felipe ^c   De Souza Passos, Luiz Fernando ^a   Ribeiro De Barros Cardoso, Cristina ^d   Cunha, Maria da Graça Souza ^e   Pôrto Dos Santos, Maísa ^a   Villarouco Silva, George Allan ^a   Silva Fraporti, Liziara ^a   De Paula, Lúcia ^a  

^a FEDERAL UNIVERSITY OF AMAZONAS   (Brazil)

^b Fundacao de Hematologia e Hemoterapia do Amazonas   (Brazil)

^c INSTITUTO LEÔNIDAS E MARIA DEANE   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e Alfredo da Matta Foundation of Tropical Dermatology and Venereology   (Brazil)

Author keywords

IL 17A mRNA; Immunity; Inflammatory cytokines; Leprosy; Mycobacterium leprae; Skin

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 17; INTERLEUKIN 23P19; INTERLEUKIN 6; MESSENGER RNA;

ADULT; ARTICLE; BACTERIAL LOAD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IL 17A GENE; IL 23P19 GENE; IL 6 GENE; IMMUNE DEFICIENCY; LEPROSY; MALE; MYCOBACTERIUM LEPRAE; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SKIN BIOPSY; TH17 CELL;

ADULT; FEMALE; HUMANS; INTERLEUKIN-17; LEPROSY; MALE; RNA, MESSENGER; SKIN DISEASES, BACTERIAL;

EID: 84865382705     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1741     Document Type: Article

References (48)

1. Scollard DM, Adams LB, Gillis TP, et al. The Continuing Challenges of Leprosy. Clin Microbiol 2006; 19(2): 338-81.
2. WHO, World Health Organization. Chemotherapy of leprosy for control programmes. WHO, Geneva, Technical Report Series 1982; n.675.
3. WHO, World Health Organization. Leprosy update, 2011.Weekly Epidemiological Record, 2011; n.36, 86: 398-400.
4. Klatser PR, Van Beers S, Madjid B, Day B, De Wit My. Detection of Mycobacterium leprae nasal carriers in populations for which leprosy is endemic. J Clin Microbiol 1993; 31: 2947-51.
5. Job CK, Jayakumar J, Kearney M, Gillis TP. Transmission of Leprosy: A Study of Skin and Nasal Secretions of Household Contacts of Leprosy Patients Using PCR. Am J Trop Med Hyg 2008; 78(3): 518-21.
6. Britton WJ, Lockwood DN. Leprosy. Lancet 2004; 363: 1209-19.
7. Modlin RL. The innate immune response in leprosy. Curr Opin Immunol 2010; 22(1): 48-54.
8. Ridley DS, Jopling WH. Classification of leprosy according to immunity: A five-group system. Int J Lepr Other Mycobact Dis 1966; 34: 255-73.
9. Arnoldi J, Gerdes J, Flad HD. Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy. Am J Pathol 1990; 137: 749-53.
10. Misra N, Murtaza A, Walker B, et al. Cytokine profile of circulating T cells of leprosy patients reflects both indiscriminate and polarized T-helper subsets: T-helper phenotype is stable and uninfluenced by related antigens of Mycobacterium leprae. Immunol 1995; 86(1): 97-103.
11. Moubasher AD, Kamel NA, Zedan H, Raheem DD. Cytokines in leprosy, I. Serum cytokine profile in leprosy. Int J Dermatol 1998; 37(10): 733-40.
12. Jadhav R, Suneetha L, Kamble R, et al. Analysis of antibody and cytokine markers for leprosy nerve damage and reactions in the INFIR cohort in India. PloS Negl Trop Dis 2011; 5(3): e977.
13. Attia EA, Abdallah M, Saad AA, et al. Circulating CD4+ CD25 high FoxP3+ T cells vary in different clinical forms of leprosy. Int J Dermatol 2010; 49(10): 1152-8.
14. Massone C, Nunzi E, Ribeiro Rodrigues R, et al. T regulatory cells and plasmocytoid dendritic cells in Hansen disease: a new insight into pathogenesis? Am J Dermatopathol 2010; 32(3): 251-6.
15. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995; 155(12): 5483-6.
16. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010; 10(7): 479-89.
17. Roark CL, Simonian PL, Fontenot AP, Born WK, O'Brien RL. Gamma delta T cells: an important source of IL-17. Curr Opin Immunol 2008; 20(3): 353-7.
18. Teixeira-Coelho M, Cruz A, Carmona J, Sousa C, Ramos-Pereira D. TLR2 deficiency by compromising p19 (IL-23) expression limits Th 17 cell responses to Mycobacterium tuberculosis. Int Immunol 2011; 23(2): 89-96.
19. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-76.
20. Hamada S, Umemura M, Shiono T, et al. IL-17A produced by gamma delta T cells plays a critical role in innate immunity against Listeria monocytogenes infection in the liver. J Immunol 2008; 181(5): 3456-63.
21. Lin Y, Ritchea S, Logar A, et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 2009; 31(5): 799-810.
22. Umemura M, Yahagi A, Hamada S, et al. IL-17-Mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis Bacille Calmette-Guérin infection. J Immunol 2007; 178: 3786-96.
23. Okamoto Yoshida Y, Umemura M, et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010; 184(8): 4414-22.
24. Moraes MO, Cardoso CC, Vanderborght PR, Pacheco AG. Genetics of host response in leprosy. Lepr Rev 2006; 77(3): 189-202.
25. Sales AM, Ponce de Leon A, Düppre NC, et al. Leprosy among patient contacts: a multilevel study of risk factors. PloS Negl Trop Dis 2011; 5(3): e1013.
26. Ochoa MT, Valderrama L, Ochoa A, Zea A, Escobar CE. Lepromatous and tuberculoid leprosy: clinical presentation and cytokine responses. Int J Dermatol 1996; 35(11): 786-90.
27. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8(9): 967-74.
28. Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD41 T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nature Immunol 2007; 8: 369-77.
29. Belgaumkar VA, Gokhale NR, Mahajan PM, et al. Circulating cytokine profiles in leprosy patients. Lepr Rev 2007; 78(3): 223-30.
30. Stefani MM, Guerra JG, Sousa AL, et al. Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report. BMC Infect Dis 2009; 9: 75.
31. Lima MC, Pereira GM, Rumjanek FD, et al. Immunological cytokine correlates of protective immunity and pathogenesis in leprosy. Scand J Immunol 2000; 51(4): 419-28.
32. Curtis MM,Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunol 2009; 126: 177-85.
33. Khader SA, Gopal R. IL-17 in protective immunity to intracellular pathogens. Virulence 2010; 1(5): 423-7.
34. Ayabe T, Satchell DP, Wilson CL, et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000; 1(2): 113-8.
35. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203(10): 2271-9.
36. Bai H, Cheng J, Gao X, et al. IL-17/Th17 promotes type 1 T cell immunity against pulmonary intracellular bacterial infection through modulating dendritic cell function. J Immunol 2009; 183(9): 5886-95.
37. Scriba TJ, Kalsdorf B, Abrahams DA, et al. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 2008; 180(3): 1962-70.
38. Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol 2009; 39(3): 723-9.
39. Lim A, Allison C, Price P, Waterer G. Susceptibility to pulmonary disease due to Mycobacterium avium-intracellulare complex may reflect low IL-17 and high IL-10 responses rather than Th1 deficiency. Clin Immunol 2010; 137(2): 296-302.
40. Chen J, Deng Y, Zhao J, Luo Z, Peng W. The polymorphism of IL-17 G-152A was associated with childhood asthma and bacterial colonization of the hypopharynx in bronchiolitis. J Clin Immunol 2010; 30(4): 539-45.
41. Murray RA, Siddiqui MR, Mendillo M, Krahenbuhl J, Kaplan G. Mycobacterium leprae inhibits dendritic cell activation and maturation. J Immunol 2007; 178(1): 338-44.
42. Sinsimer D, Fallows D, Peixoto B, Krahenbuhl J, Kaplan G, Manca C. Mycobacterium leprae actively modulates the cytokine response in naive human monocytes. Infect Immun 2010; 78(1): 293-300.
43. Tilg H, Moschen AR, Kaser A. Suppression of interleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression? Eur Cytokine Netw 2009; 20(1): 1-6.
44. Lim A, Allison C, Price P, Waterer G. Susceptibility to pulmonary disease due to Mycobacterium avium-intracellulare complex may reflect low IL-17 and high IL-10 responses rather than Th1 deficiency. Clin Immunol 2010; 137(2): 296-302.
45. Cardoso CC, Pereira AC, de Sales Marques C, Moraes MO. Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome. Future Microbiol 2011; 6: 533-49.
46. Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J Med 2009; 361(27): 2609-18.
47. Lala S, Ogura Y, Osborne C, et al. Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterol 2003; 125(1): 47-57.
48. Schurr E, Gros P. A common genetic fingerprint in leprosy and Crohn's disease? N Engl J Med 2009; 361(27): 2666-8.